Acute coronary syndrome and renal dysfunction
https://doi.org/10.20996/1819-6446-2016-12-1-72-78
Abstract
Renal dysfunction in patients with acute coronary syndrome complicates the diagnosis, worsens the short- and long-term prognosis, reduces the effectiveness of the reperfusion therapy, and increases the risk of bleeding. It is important to aim for treatment based on the evidence-based studies and according to the updated guidelines of the professional associations.
About the Author
F. I. Belyalov
Irkutsk State Medical Academy of Postgraduate Education. Microrion Yubileiniy 100, Irkutsk, 664079 Russia
Russian Federation
Russian Federation
References
1. Gupta T, Harikrishnan P, Kolte D et al. Trends in Management and Outcomes of ST-Elevation Myocardial Infarction in Patients With End-Stage Renal Disease in the United States. he American journal of cardiology 2015;115:1033-41.
2. Fox CS, Muntner P, Chen AY et al. Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non—ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease. Circulation 2010;121:357-65.
3. Silva D, Cortez-Dias N, Jorge C et al. Cystatin C as Prognostic Biomarker in ST-Segment Elevation Acute Myocardial Infarction. The American journal of cardiology 2012;109(10):1431-8.
4. Hlatky MA, Shilane D, Chang TI, et al. Incremental prognostic information from kidney function in patients with new onset coronary heart disease. American heart journal 2014;167(1):86-92.
5. Gibson CM, Dumaine RL, Gelfand EV et al. Association of glomerular filtration rate on presentation with subsequent mortality in non—ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. Eur Heart J 2004;25(22):1998-2005
6. Gibson C.M., Pinto D.C., Murphy S.A et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535-43.
7. Bae EH, Lim SY, Cho KH et al. GFR and Cardiovascular Outcomes After Acute Myocardial Infarction: Results From the Korea Acute Myocardial Infarction Registry. American journal of kidney diseases 2012;59(6):795-802.
8. Orvin K, Eisen A, Goldenberg I et al. The proxy of renal function that most accurately predicts shortand long-term outcome after acute coronary syndrome. American Heart Journal 2015;169:702-12.e3.
9. Dohi T, Kasai T, Miyauchi K et al. Prognostic impact of chronic kidney disease on 10-year clinical outcomes among patients with acute coronary syndrome. J Cardiol 2012;60(6):438-42.
10. Fox CS, Muntner P, Chen AY et al. Short-Term Outcomes of Acute Myocardial Infarction in Patients With Acute Kidney Injury. Circulation 2012;125(3):497-504.
11. Goldberg A, Kogan E, Hammerman H. et al. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney International 2009;76:900-6.
12. Choi JS, Kim YA, Kim MJ et al. Relation Between Transient or Persistent Acute Kidney Injury and Long-Term Mortality in Patients With Myocardial Infarction. The American journal of cardiology 2013;112(1):41-5.
13. Marenzi G, Cabiati A, Cosentino N et al. Prognostic significance of serum creatinine and its change patterns in patients with acute coronary syndromes. American Heart Journal 2015;169:363-70.
14. KDIGO clinical practice guideline for evaluation and management of CKD. Kidney Int 2013;Suppl 3:1- 150.
15. Venetsanos D, Alfredsson J, Segelmark M et al. Glomerular filtration rate (GFR) during and after STEMI: a single-centre, methodological study comparing estimated and measured GFR. BMJ Open 2015;5(9):e007835.
16. Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, et al. Which method of GFR estimation has the best prognostic value in patients treated with primary PCI: Cockcroft-Gault formula, MDRD, or CKD-EPI equation? – A 6-year follow-up. Ren Fail 2011;33(10):983-9.
17. Szummer K, Lundman P, Jacobson SH, et al. Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction. American heart journal 2010;159(6):979-86.
18. Choi JS, Kim CS, Bae EH, et al. Predicting outcomes after myocardial infarction by using the Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the MDRD study equation. Nephrol Dial Transplant 2012;27(10):3868-74.
19. Melloni C, Peterson ED, Chen AY et al. Cockcroft-Gault Versus Modification of Diet in Renal Disease: Importance of GFR Formula for Classification of CKD in Patients With Non—ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 2008;51:991-6.
20. Sosnov J, Lessard D, Goldberg RJ et al. Differential Symptoms of Acute Myocardial Infarction in Patients With Kidney Disease: A Community-Wide Perspective. AJKD 2006;47:378-84.
21. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. American heart journal 2012;163(3):399-406.
22. Stacy SR, Suarez-Cuervo C, Berger Z, et al. Role of Troponin in Patients With Chronic Kidney Disease and Suspected Acute Coronary Syndrome: A Systematic Review. Ann Intern Med 2014;161:502-512.
23. Pfortmueller CA, Funk G-C, Marti G. et al. Diagnostic Performance of High-Sensitive Troponin T in Patients With Renal Insufficiency. The American journal of cardiology 2013;112(12):1968-72.
24. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37(3):267-315.
25. Veljkov VV. The new universal definition of myocardial infarction: critical high-sensitivity troponin - relevance for cardiology and cardiac surgery. Moscow: ZAO Diakon; 2015. In Russian (Вельков В.В. Новое универсальное определение инфаркта миокарда: решающее значение высокочувствительных тропонинов – актуальность для кардиологии и кардиохирургии. Москва: ЗАО Диакон; 2015).
26. Aviles RJ, Askari AT, Lindahl B et al. Troponin T Levels in Patients with Acute Coronary Syndromes, with or without Renal Dysfunction. NEJM 2002;346:2047-52.
27. Fehr T, Knoflach A, Ammann P et al. Differential use of cardiac troponin T versus I in hemodialysis patients. Clin Nephrol 2003;59(1):35-9.
28. Freda BJ, Tang WH, Van Lente F et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40:2065-71.
29. Lamb EJ, Kenny C, Abbas NA et al. Cardiac Troponin I Concentration Is Commonly Increased in Nondialysis Patients With CKD: Experience With a Sensitive Assay. AJKD 2007;49:507-16.
30. Nakai K, Nakai K, Nagane Y et al. Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure. Clin Exp Nephrol 2004;8(1):43-7.
31. Usman B, Annapoorna SK, Samin KS et al. Thrombolysis In Myocardial Infarction (TIMI) Risk Score
32. and Mortality in Patients With Advanced Chronic Kidney Disease and on Dialysis. The American journal of cardiology. 2009;103(11):1513-7.
33. Go J, Narmi A, Sype J, et al. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. Coron Artery Dis 2011;22(6):411-5.
34. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006;70:2021-30.
35. Coca SG, Krumholz HM, Garg AX et al. Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease. JAMA 2006;296:1377-84.
36. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 2011;58(22):2263-9.
37. Washam JB, Herzog CA, Beitelshees AL et al. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circulation 2015;131(12):1123-49.
38. Yan AT, Yan RT, Tan M, Constance C, et al. Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. Can J Cardiol 2006;22(2):115-20.
39. Gibson CM, Pinto DS, Murphy SA et al., TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535-43.
40. Medi C, Montalescot G, Budaj A et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv 2009;2(1):26-33.
41. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362-425.
42. Vasu S, Gruberg L, Brown DL. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2007;70(5):701-5.
43. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4(9):1011-9.
44. Nauta ST, van Domburg RT, Nuis RJ, et al. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. Kidney Int 2013;84(2):353-8.
45. Huang HD, Alam M, Hamzeh I, et al. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol 2013;168(4):3741-6.
46. Szummer K, Lundman P, Jacobson SH, et al. Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction. Circulation 2009;120(10):851-8.
47. Sadeghi HM, Stone GW, Grines CL et al. Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003;108:2769-75.
48. Hanna EB, Chen AY, Roe MT, Saucedo JF. Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically. AHJ 2012;164:52-7.
49. Marenzi G, Cabiati A, Bertoli SV et al. Incidence and Relevance of Acute Kidney Injury in Patients Hospitalized With Acute Coronary Syndromes. The American journal of cardiology 2013;111(6):816-22.
50. Takeshi S., Masayuki M., Hiroshi K et al. Contrast-Induced Nephropathy in Patients Undergoing Emergency Percutaneous Coronary Intervention for Acute Coronary Syndrome. The American journal of cardiology 2010;105(5):624-8.
51. Wichmann JL, Katzberg RW, Litwin SE, et al. Contrast-Induced Nephropathy. Circulation 2015;132(20):1931-6.
52. Shacham Y, Leshem-Rubinow E, Gal-Oz A et al. Association of Left Ventricular Function and Acute Kidney Injury Among ST-Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Intervention. American Journal of Cardiology 2015;115:293-7.
53. Nemoto N, Iwasaki M, Nakanishi M et al. Impact of Continuous Deterioration of Kidney Function 6 to 8 Months After Percutaneous Coronary Intervention for Acute Coronary Syndrome. The American journal of cardiology 2014;113:1647-51.
54. James MT, Tonelli M, Ghali WA et al. Renal outcomes associated with invasive versus conservative management of acute coronary syndrome: propensity matched cohort study. BMJ 2013;347:f4151.
55. Han JH, Chandra A, Mulgund J et al. Chronic Kidney Disease in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. AJM 2006;119:248-54
56. Winkelmayer WC, Charytan DM, Brookhart MA et al. Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. Clin J Am Soc Nephrol 2006;1:796-801.
57. Ariza-SoléA, Sánchez-Elvira G, Sánchez-Salado JC et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2013;132(6):652-8.
58. Flores-Ríos X, Couto-Mallón D, Rodríguez-Garrido J et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI. Eur Heart J Acute Cardiovasc Care 2013;2(1):19-26.
59. Garcia DA, Baglin TP, Weitz JI et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2_suppl): e24S-43S.
60. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-84.
61. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41.
62. Giraldez RR, Nicolau JC, Corbalan R et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic. Eur Heart J 2007;28(13):1566-73.
63. Fox KAA, Bassand JP, Mehta SR et al. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes. Ann Intern Med 2007; 147:304-10.
64. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
65. Htun P, Fateh-Moghadam S, Bischofs C, et al. Low Responsiveness to Clopidogrel Increases Risk among CKD Patients Undergoing Coronary Intervention. JASN 2011;22(4):627-33.
66. Sang HP, Weon K, Chung SP et al. A Comparison of Clopidogrel Responsiveness in Patients With Versus Without Chronic Renal Failure. The American journal of cardiology. 2009;104(9):1292-5.
67. Palmer SC, Di Micco L, Razavian M, et al. Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. Ann Intern Med 2012;156(6):445-59.
68. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008; 155(4): 687-93.
69. Ahmed S, Gibson MC, Cannon CP, et al. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis 2011;31:493-500.
70. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14(2):312-8.
71. James S, Budaj A, Aylward P. et al. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122(11):1056-67.
72. Magnani G, Storey RF, Steg G et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J 2016;37(4):400-8.
73. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 2012;52(9):1388-98.
74. Dinicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-Angiotensin receptor blocker interaction? Clin Cardiol 2012;35(11):647-8.
75. Wright RS, Reeder GS, Herzog CA et al. Acute Myocardial Infarction and Renal Dysfunction: A High- Risk Combination. Ann Intern Med 2002;137:563-70.
76. Berger AK, Duval S, Krumholz HM et el. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42:201-8.
77. Keough-Ryan TM, Kiberd BA, Dipchand CS et al. Outcomes of Acute Coronary Syndrome in a Large Canadian Cohort: Impact of Chronic Renal Insufficiency, Cardiac Interventions, and Anemia. American Journal of Kidney Diseases 2005;46(5):845-55.
78. Reddan DN, Szczech L, Bhapkar MV, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 2005;20(10):2105-12.
79. Szummer K, Lundman P, Jacobson SH . et al. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011;79:997-1004.
80. Lim SY, Bae EH, Choi JS, et al. Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction. The American journal of cardiology 2012;109(10):1425-30.
81. Keough-Ryan TM, Kiberd BA, Dipchand CS et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005;46:845-55.
82. Smith DH, Johnson ES, Boudreau DM et al. Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study. The American Journal of Medicine 2015;128:1252.e1-11.
83. KDIGO Clinical Practice Guideline for Lipid Management In Chronic Kidney Disease. Kidney inter 2013;3 (suppl):259-305.
Review
For citations:
Belyalov F.I. Acute coronary syndrome and renal dysfunction. Rational Pharmacotherapy in Cardiology. 2016;12(1):72-78. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-1-72-78
Views:
988
.jpg)
Email this article 